Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

1.03
-0.0400-3.76%
Post-market: 1.050.0248+2.42%17:08 EDT
Volume:22.09M
Turnover:23.06M
Market Cap:346.98M
PE:-4.02
High:1.10
Open:1.10
Low:1.01
Close:1.07
52wk High:2.73
52wk Low:1.01
Shares:338.52M
Float Shares:327.56M
Volume Ratio:2.11
T/O Rate:6.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2551
EPS(LYR):-0.2260
ROE:-660.00%
ROA:-48.44%
PB:-20.96
PE(LYR):-4.53

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks

Reuters
·
Apr 01

BUZZ-Ocugen rises after finishing patient dosing in late-stage eye gene therapy trial

Reuters
·
Apr 01

Ocugen completes dosing in Phase 2/3 Stargardt gene therapy trial ahead of schedule

Reuters
·
Apr 01

Ocugen Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Apr 01

Ocugen Inc. Stock Slips 6.4%, Underperforms Market

Dow Jones
·
Mar 31

Ocugen Inc. Stock Sheds 4.6%, Underperforms Market

Dow Jones
·
Mar 28

Assessing Ocugen (OCGN) Valuation After Recent Share Price Volatility And Long Term Momentum

Simply Wall St.
·
Mar 27

Canaccord Genuity Sticks to Its Buy Rating for Ocugen (OCGN)

TIPRANKS
·
Mar 26

Ocugen Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Mar 26

Ocugen: Encouraging Phase 2 OCU410 Data in Geographic Atrophy Underpin Buy Rating and Long-Term Upside Potential

TIPRANKS
·
Mar 26

Is Ocugen (OCGN) Pricing Make Sense After Its Volatile Multi‑Year Share Price Swings

Simply Wall St.
·
Mar 25

Ocugen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Ocugen price target raised to $10 from $7 at H.C. Wainwright

TIPRANKS
·
Mar 25

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Mar 24

Ocugen Reports Positive Phase 2 Trial Data For Eye Disease Therapy

MT Newswires Live
·
Mar 24

BUZZ- Ocugen rises as gene therapy slows vision loss in advanced eye disease trial

Reuters
·
Mar 24

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

TIPRANKS
·
Mar 24

Ocugen reports 31% lesion growth reduction at 12 months in Phase 2 ArMaDa trial of OCU410 for geographic atrophy

Reuters
·
Mar 24

Ocugen Inc - to Initiate Ocu410 Phase 3 Registrational Trial in Q3 2026

THOMSON REUTERS
·
Mar 24

Ocugen Announces Topline 12-Month Data From Phase 2 Armada Clinical Trial Evaluating Ocu410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

THOMSON REUTERS
·
Mar 24